메뉴 건너뛰기




Volumn 27, Issue 4, 2012, Pages 458-468

Therapeutic modalities in diabetic nephropathy: Standard and emerging approaches

Author keywords

Diabetes mellitus; Disease management; Measurement; Nephropathy; Therapeutic strategies

Indexed keywords

ALBUMIN; ALISKIREN; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BARDOXOLONE METHYL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; EPLERENONE; GLITAZONE DERIVATIVE; GLUCOSE; HYPOCHOLESTEROLEMIC AGENT; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; PARICALCITOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SPIRONOLACTONE; TELMISARTAN; VALSARTAN;

EID: 84862525384     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-011-1912-5     Document Type: Review
Times cited : (46)

References (213)
  • 1
    • 84862557038 scopus 로고    scopus 로고
    • USRDS TUSRDS. Annual Data Report. Bethesda: The National Institutes of Diabetes and Digestive and Kidney Diseases
    • USRDS TUSRDS. Annual Data Report. Bethesda: The National Institutes of Diabetes and Digestive and Kidney Diseases; 2005.
    • (2005)
  • 2
    • 0141819203 scopus 로고    scopus 로고
    • Proteinuria and other markers of chronic kidney disease: A position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    • DOI 10.1016/S0272-6386(03)00826-6
    • Eknoyan G,Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: A position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003;42:617-22. (Pubitemid 37187362)
    • (2003) American Journal of Kidney Diseases , vol.42 , Issue.4 , pp. 617-622
    • Eknoyan, G.1    Hostetter, T.2    Bakris, G.L.3    Hebert, L.4    Levey, A.S.5    Parving, H.-H.6    Steffes, M.W.7    Toto, R.8    Willis, K.9
  • 3
    • 20844448302 scopus 로고    scopus 로고
    • Diabetic nephropathy: Linking histology, cell biology, and genetics
    • Adler S. Diabetic nephropathy: Linking histology, cell biology, and genetics. Kidney Int. 2004;66:2095-106.
    • (2004) Kidney Int , vol.66 , pp. 2095-106
    • Adler, S.1
  • 4
    • 0021236983 scopus 로고
    • Predicting diabetic nephropathy in insulin-dependent patients
    • Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984;311:89-93. (Pubitemid 14084080)
    • (1984) New England Journal of Medicine , vol.311 , Issue.2 , pp. 89-93
    • Mogensen, C.E.1    Christensen, C.K.2
  • 5
    • 0033850165 scopus 로고    scopus 로고
    • The need for early predictors of diabetic nephropathy risk: Is albumin excretion rate sufficient?
    • Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: Is albumin excretion rate sufficient? Diabetes. 2000;49:1399-408.
    • (2000) Diabetes , vol.49 , pp. 1399-408
    • Caramori, M.L.1    Fioretto, P.2    Mauer, M.3
  • 6
    • 33645450441 scopus 로고    scopus 로고
    • Enhancing the predictive value of urinary albumin for diabetic nephropathy
    • Caramori ML, Fioretto P, Mauer M. Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol. 2006;17:339-52.
    • (2006) J Am Soc Nephrol , vol.17 , pp. 339-52
    • Caramori, M.L.1    Fioretto, P.2    Mauer, M.3
  • 7
    • 0345505677 scopus 로고    scopus 로고
    • Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: An indicator of more advanced glomerular lesions
    • DOI 10.2337/diabetes.52.4.1036
    • Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: An indicator of more advanced glomerular lesions. Diabetes. 2003;52:1036-40. (Pubitemid 36384275)
    • (2003) Diabetes , vol.52 , Issue.4 , pp. 1036-1040
    • Caramori, M.L.1    Fioretto, P.2    Mauer, M.3
  • 10
    • 33644875787 scopus 로고    scopus 로고
    • Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy
    • Nguyen TQ, Tarnow L, Andersen S, et al. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29:83-8. (Pubitemid 44033436)
    • (2006) Diabetes Care , vol.29 , Issue.1 , pp. 83-88
    • Nguyen, T.Q.1    Tarnow, L.2    Andersen, S.3    Hovind, P.4    Parving, H.-H.5    Goldschmeding, R.6    Van Nieuwenhoven, F.A.7
  • 12
    • 0141674965 scopus 로고    scopus 로고
    • Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats
    • DOI 10.1046/j.1523-1755.2003.00237.x
    • Kalantarinia K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003;64:1208-13. (Pubitemid 37153785)
    • (2003) Kidney International , vol.64 , Issue.4 , pp. 1208-1213
    • Kalantarinia, K.1    Awad, A.S.2    Siragy, H.M.3
  • 13
    • 0033833789 scopus 로고    scopus 로고
    • Urinary excretion of podocytes in patients with diabetic nephropathy
    • Nakamura T, Ushiyama C, Suzuki S, et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant. 2000;15:1379-83.
    • (2000) Nephrol Dial Transplant , vol.15 , pp. 1379-83
    • Nakamura, T.1    Ushiyama, C.2    Suzuki, S.3
  • 14
    • 66849091695 scopus 로고    scopus 로고
    • Neutrophil Gelatinase-Associated Lipocalin (NGAL) and progression of chronic kidney disease
    • Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:337-44.
    • (2009) Clin J Am Soc Nephrol , vol.4 , pp. 337-44
    • Bolignano, D.1    Lacquaniti, A.2    Coppolino, G.3
  • 15
    • 79551536740 scopus 로고    scopus 로고
    • Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetylbeta-D-glucosaminidase
    • Vaidya VS, Niewczas MA, Ficociello LH, et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetylbeta-D- glucosaminidase. Kidney Int. 2011;79:464-70.
    • (2011) Kidney Int , vol.79 , pp. 464-70
    • Vaidya, V.S.1    Niewczas, M.A.2    Ficociello, L.H.3
  • 16
    • 0027370108 scopus 로고
    • The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
    • The Diabetes Control and Complications Trial Research Group
    • The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
    • (1993) N Engl J Med , vol.329 , pp. 977-986
  • 18
    • 0142087597 scopus 로고    scopus 로고
    • Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study
    • Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159-2167.
    • (2003) JAMA , vol.290 , pp. 2159-2167
  • 21
    • 53749096863 scopus 로고    scopus 로고
    • 10-year follow-up of intensive glucose control in type 2 diabetes
    • Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.
    • (2008) N Engl J Med , vol.359 , pp. 1577-89
    • Holman, R.R.1    Paul, S.K.2    Bethel, M.A.3
  • 22
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33
    • UK Prospective Diabetes Study (UKPDS) Group
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
    • (1998) Lancet , vol.352 , pp. 837-853
  • 24
    • 77955585592 scopus 로고    scopus 로고
    • Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial
    • Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet. 2010;376:419-30.
    • (2010) Lancet , vol.376 , pp. 419-30
    • Ismail-Beigi, F.1    Craven, T.2    Banerji, M.A.3
  • 25
    • 58149389215 scopus 로고    scopus 로고
    • Glucose control and vascular complications in veterans with type 2 diabetes
    • Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-39.
    • (2009) N Engl J Med , vol.360 , pp. 129-39
    • Duckworth, W.1    Abraira, C.2    Moritz, T.3
  • 26
    • 0014093712 scopus 로고
    • Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy
    • Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967;61:827-37.
    • (1967) Surgery , vol.61 , pp. 827-37
    • Kelly, W.D.1    Lillehei, R.C.2    Merkel, F.K.3
  • 27
    • 0002155673 scopus 로고    scopus 로고
    • Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of October 2002
    • Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of October 2002. Clin Transplant. 2002;2002:41-77.
    • (2002) Clin Transplant , vol.2002 , pp. 41-77
    • Gruessner, A.C.1    Sutherland, D.E.2
  • 30
    • 0027493382 scopus 로고
    • Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys
    • DOI 10.1016/0140-6736(93)92183-T
    • Fioretto P, Mauer SM, Bilous RW, et al. Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet. 1993;342:1193-6. (Pubitemid 23331708)
    • (1993) Lancet , vol.342 , Issue.8881 , pp. 1193-1196
    • Fioretto, P.1    Mauer, S.M.2    Bilous, R.W.3    Goetz, F.C.4    Sutherland, D.E.R.5    Steffes, M.W.6
  • 32
    • 46449117004 scopus 로고    scopus 로고
    • The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: A decision analysis
    • Huang ES, Zhang Q, Gandra N, et al. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: A decision analysis. Ann Intern Med. 2008;149:11-9.
    • (2008) Ann Intern Med , vol.149 , pp. 11-9
    • Huang, E.S.1    Zhang, Q.2    Gandra, N.3
  • 33
    • 0019965181 scopus 로고
    • Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy
    • Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed). 1982;285:685-8. (Pubitemid 12051454)
    • (1982) British Medical Journal , vol.285 , Issue.6343 , pp. 685-688
    • Mogensen, C.E.1
  • 34
    • 0036190137 scopus 로고    scopus 로고
    • Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes
    • DOI 10.1046/j.1523-1755.2002.00213.x
    • Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086-97. (Pubitemid 34175478)
    • (2002) Kidney International , vol.61 , Issue.3 , pp. 1086-1097
    • Schrier, R.W.1    Estacio, R.O.2    Esler, A.3    Mehler, P.4
  • 35
    • 0032511580 scopus 로고    scopus 로고
    • Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
    • UK Prospective Diabetes Study Group
    • Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
    • (1998) BMJ , vol.317 , pp. 703-713
  • 36
    • 7344263454 scopus 로고    scopus 로고
    • Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
    • UK Prospective Diabetes Study Group
    • Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ. 1998;317:720-726.
    • (1998) BMJ , vol.317 , pp. 720-726
  • 37
    • 34548420712 scopus 로고    scopus 로고
    • Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial
    • DOI 10.1016/S0140-6736(07)61303-8, PII S0140673607613038
    • Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007;370:829-40. (Pubitemid 47362321)
    • (2007) Lancet , vol.370 , Issue.9590 , pp. 829-840
    • Patel, A.1
  • 38
    • 65249111029 scopus 로고    scopus 로고
    • Lowering blood pressure reduces renal events in type 2 diabetes
    • de Galan BE, Perkovic V, Ninomiya T, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009;20:883-92.
    • (2009) J Am Soc Nephrol , vol.20 , pp. 883-92
    • De Galan, B.E.1    Perkovic, V.2    Ninomiya, T.3
  • 40
    • 11844259382 scopus 로고    scopus 로고
    • Standards of medical care in diabetes
    • Standards of medical care in diabetes. Diabetes Care. 2005;28(Suppl 1):S4-S36.
    • (2005) Diabetes Care , vol.28 , Issue.SUPPL. 1
  • 41
    • 3042819708 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease
    • K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1-290.
    • (2004) Am J Kidney Dis , vol.43
  • 42
    • 77951735232 scopus 로고    scopus 로고
    • Effects of intensive blood-pressure control in type 2 diabetes mellitus
    • Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010.
    • (2010) N Engl J Med
  • 44
    • 0028867689 scopus 로고
    • Prevention of diabetic renal disease with special reference to microalbuminuria
    • Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346:1080-4.
    • (1995) Lancet , vol.346 , pp. 1080-4
    • Mogensen, C.E.1    Keane, W.F.2    Bennett, P.H.3
  • 45
    • 0027049331 scopus 로고
    • Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
    • Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med. 1993;118:129-38.
    • (1993) Ann Intern Med , vol.118 , pp. 129-38
    • Kasiske, B.L.1    Kalil, R.S.2    Ma, J.Z.3
  • 46
    • 0029857846 scopus 로고    scopus 로고
    • Appropriate blood pressure control in NIDDM (ABCD) Trial
    • DOI 10.1007/s001250050629
    • Schrier RW, Estacio RO, Jeffers B. Appropriate Blood Pressure Control in NIDDM (ABCD) trial. Diabetologia. 1996;39:1646-54. (Pubitemid 26397382)
    • (1996) Diabetologia , vol.39 , Issue.12 , pp. 1646-1654
    • Schrier, R.W.1    Estacio, R.O.2    Jeffers, B.3
  • 47
    • 0032513878 scopus 로고    scopus 로고
    • Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
    • DOI 10.1016/S0140-6736(98)04311-6
    • Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62. (Pubitemid 28269185)
    • (1998) Lancet , vol.351 , Issue.9118 , pp. 1755-1762
    • Hansson, L.1    Zanchetti, A.2    Carruthers, S.G.3    Dahlof, B.4    Elmfeldt, D.5    Julius, S.6    Menard, J.7    Rahn, K.H.8    Wedel, H.9    Westerling, S.10
  • 50
    • 79959811620 scopus 로고    scopus 로고
    • Diabetes, hypertension, and outcome studies: Overview 2010
    • Nilsson PM, Cederholm J. Diabetes, hypertension, and outcome studies: Overview 2010. Diabetes Care. 2011;34(Suppl 2):S109-13.
    • (2011) Diabetes Care , vol.34 , Issue.SUPPL. 2
    • Nilsson, P.M.1    Cederholm, J.2
  • 51
    • 0037898667 scopus 로고    scopus 로고
    • Treatment of hypertension in adults with diabetes
    • Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26(Suppl 1):S80-2. (Pubitemid 36928963)
    • (2003) Diabetes Care , vol.26 , Issue.SUPPL. 1
    • Arauz-Pacheo, C.1    Parrott, M.A.2    Raskin, P.3
  • 53
    • 77951735232 scopus 로고    scopus 로고
    • Effects of intensive blood-pressure control in type 2 diabetes mellitus
    • Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85.
    • (2010) N Engl J Med , vol.362 , pp. 1575-85
    • Cushman, W.C.1    Evans, G.W.2    Byington, R.P.3
  • 54
    • 77954374543 scopus 로고    scopus 로고
    • Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease
    • Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-8.
    • (2010) JAMA , vol.304 , pp. 61-8
    • Cooper-DeHoff, R.M.1    Gong, Y.2    Handberg, E.M.3
  • 55
    • 77957259177 scopus 로고    scopus 로고
    • Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: An observational study from the Swedish national diabetes register
    • Cederholm J, Gudbjornsdottir S, Eliasson B, et al. Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: An observational study from the Swedish national diabetes register. J Hypertens. 2010;28:2026-35.
    • (2010) J Hypertens , vol.28 , pp. 2026-35
    • Cederholm, J.1    Gudbjornsdottir, S.2    Eliasson, B.3
  • 56
    • 0025028032 scopus 로고
    • Prostaglandins, angiotension II, and proteinuria
    • Dunn MJ. Prostaglandins, angiotension II, and proteinuria. Nephron. 1990;55(Suppl 1):30-7.
    • (1990) Nephron , vol.55 , Issue.SUPPL. 1 , pp. 30-7
    • Dunn, M.J.1
  • 60
    • 65249126924 scopus 로고    scopus 로고
    • Supramaximal dose of candesartan in proteinuric renal disease
    • Burgess E, Muirhead N, Rene de Cotret P, et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009;20:893-900.
    • (2009) J Am Soc Nephrol , vol.20 , pp. 893-900
    • Burgess, E.1    Muirhead, N.2    Rene De Cotret, P.3
  • 61
    • 38049139424 scopus 로고    scopus 로고
    • Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease
    • Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30-48. (Pubitemid 351688350)
    • (2008) Annals of Internal Medicine , vol.148 , Issue.1 , pp. 30-48
    • Kunz, R.1    Friedrich, C.2    Wolbers, M.3    Mann, J.F.E.4
  • 62
    • 49149087718 scopus 로고    scopus 로고
    • Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial
    • Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-53.
    • (2008) Lancet , vol.372 , pp. 547-53
    • Mann, J.F.1    Schmieder, R.E.2    McQueen, M.3
  • 63
    • 0030908772 scopus 로고    scopus 로고
    • Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
    • Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997;349:1787-1792.
    • (1997) The EUCLID Study Group. Lancet , vol.349 , pp. 1787-1792
  • 64
    • 0032525867 scopus 로고    scopus 로고
    • Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: A randomized, controlled trial
    • Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128:982-8. (Pubitemid 28275174)
    • (1998) Annals of Internal Medicine , vol.128 , Issue.12 PART 1 , pp. 982-988
    • Ravid, M.1    Brosh, D.2    Levi, Z.3    Bar-Dayan, Y.4    Ravid, D.5    Rachmani, R.6
  • 65
    • 0034074955 scopus 로고    scopus 로고
    • Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes
    • Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2): B54-64. (Pubitemid 30185779)
    • (2000) Diabetes Care , vol.23 , Issue.SUPPL. 2
    • Estacio, R.O.1    Jeffers, B.W.2    Gifford, N.3    Schrier, R.W.4
  • 66
    • 0027517013 scopus 로고
    • Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
    • Ravid M, Savin H, Jutrin I, et al. Long-term stabilization of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118:577-81. (Pubitemid 23102690)
    • (1993) Annals of Internal Medicine , vol.118 , Issue.8 , pp. 577-581
    • Ravid, M.1    Savin, H.2    Jutrin, I.3    Bental, T.4    Katz, B.5    Lishner, M.6
  • 67
    • 0033917552 scopus 로고    scopus 로고
    • Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy
    • DOI 10.1046/j.1523-1755.2000.00880.x
    • Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int. 2000;57:601-6. (Pubitemid 30430652)
    • (2000) Kidney International , vol.57 , Issue.2 , pp. 601-606
    • Andersen, S.1    Tarnow, L.2    Rossing, P.3    Hansen, B.V.4    Parving, H.-H.5
  • 68
    • 0035922441 scopus 로고    scopus 로고
    • Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    • Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.
    • (2001) N Engl J Med , vol.345 , pp. 861-9
    • Brenner, B.M.1    Cooper, M.E.2    De Zeeuw, D.3
  • 69
    • 0035922447 scopus 로고    scopus 로고
    • Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
    • Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
    • (2001) N Engl J Med , vol.345 , pp. 851-60
    • Lewis, E.J.1    Hunsicker, L.G.2    Clarke, W.R.3
  • 70
    • 0035922444 scopus 로고    scopus 로고
    • The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
    • Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-8.
    • (2001) N Engl J Med , vol.345 , pp. 870-8
    • Parving, H.H.1    Lehnert, H.2    Brochner-Mortensen, J.3
  • 71
    • 0027517659 scopus 로고
    • The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
    • DOI 10.1056/NEJM199311113292004
    • Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-62. (Pubitemid 23335891)
    • (1993) New England Journal of Medicine , vol.329 , Issue.20 , pp. 1456-1462
    • Lewis, E.J.1    Hunsicker, L.G.2    Bain, R.P.3    Rohde, R.D.4
  • 72
    • 0026707841 scopus 로고
    • Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive response?
    • van den Meiracker AH, AJ Man in 't Veld, Admiraal PJ, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive response? J Hypertens. 1992;10:803-12.
    • (1992) J Hypertens , vol.10 , pp. 803-12
    • Van Den Meiracker, A.H.1    Admiraal, P.J.2
  • 73
    • 34548163060 scopus 로고    scopus 로고
    • The incidence and implications of aldosterone breakthrough
    • DOI 10.1038/ncpneph0575, PII NCPNEPH0575
    • Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3:486-92. (Pubitemid 47313030)
    • (2007) Nature Clinical Practice Nephrology , vol.3 , Issue.9 , pp. 486-492
    • Bomback, A.S.1    Klemmer, P.J.2
  • 74
    • 44849124747 scopus 로고    scopus 로고
    • Aliskiren and dual therapy in type 2 diabetes mellitus
    • DOI 10.1056/NEJMe0803375
    • Ingelfinger JR. Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med. 2008;358:2503-5. (Pubitemid 351793025)
    • (2008) New England Journal of Medicine , vol.358 , Issue.23 , pp. 2503-2505
    • Ingelfinger, J.R.1
  • 75
    • 0036372173 scopus 로고    scopus 로고
    • Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): Comparison with enalapril
    • Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): Comparison with enalapril. Hypertension. 2002;39:E1-8.
    • (2002) Hypertension , vol.39
    • Nussberger, J.1    Wuerzner, G.2    Jensen, C.3
  • 76
    • 9644287897 scopus 로고    scopus 로고
    • Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption
    • DOI 10.1097/01.ASN.0000146686.35541.29
    • Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126-33. (Pubitemid 39578845)
    • (2004) Journal of the American Society of Nephrology , vol.15 , Issue.12 , pp. 3126-3133
    • Azizi, M.1    Menard, J.2    Bissery, A.3    Guyenne, T.-T.4    Bura-Riviere, A.5    Vaidyanathan, S.6    Camisasca, R.P.7
  • 77
    • 34548818515 scopus 로고    scopus 로고
    • Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals
    • Azizi M, Menard J, Bissery A, et al. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol. 2007;2:947-55.
    • (2007) Clin J Am Soc Nephrol , vol.2 , pp. 947-55
    • Azizi, M.1    Menard, J.2    Bissery, A.3
  • 78
    • 34447521458 scopus 로고    scopus 로고
    • Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial
    • DOI 10.1016/S0140-6736(07)61124-6, PII S0140673607611246
    • Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet. 2007;370:221-9. (Pubitemid 47069535)
    • (2007) Lancet , vol.370 , Issue.9583 , pp. 221-229
    • Oparil, S.1    Yarows, S.A.2    Patel, S.3    Fang, H.4    Zhang, J.5    Satlin, A.6
  • 82
    • 57049133582 scopus 로고    scopus 로고
    • The effects of spironolactone on nephron function in patients with diabetic nephropathy
    • Ustundag A, Tugrul A, Ustundag S, et al. The effects of spironolactone on nephron function in patients with diabetic nephropathy. Ren Fail. 2008;30:982-91.
    • (2008) Ren Fail , vol.30 , pp. 982-91
    • Ustundag, A.1    Tugrul, A.2    Ustundag, S.3
  • 83
    • 58149125532 scopus 로고    scopus 로고
    • Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: Results of a randomized, placebo-controlled, double-blind, crossover trial
    • Saklayen MG, Gyebi LK, Tasosa J, et al. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: Results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med. 2008;56:714-9.
    • (2008) J Investig Med , vol.56 , pp. 714-9
    • Saklayen, M.G.1    Gyebi, L.K.2    Tasosa, J.3
  • 84
    • 58049209809 scopus 로고    scopus 로고
    • Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats
    • Kang YS, Ko GJ, Lee MH, et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant. 2009;24:73-84.
    • (2009) Nephrol Dial Transplant , vol.24 , pp. 73-84
    • Kang, Y.S.1    Ko, G.J.2    Lee, M.H.3
  • 85
    • 0001847493 scopus 로고    scopus 로고
    • Eplerenone 021 Investigators. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria
    • Epstein M, Buckalew VJ, Martinez F, Altamirano J, Roniker B, Kleiman J, Krause S, Eplerenone 021 Investigators. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertens. 2002;15:24A.
    • (2002) Am J Hypertens , vol.15
    • Epstein, M.1    Buckalew, V.J.2    Martinez, F.3    Altamirano, J.4    Roniker, B.5    Kleiman, J.6    Krause, S.7
  • 86
    • 2342559832 scopus 로고    scopus 로고
    • The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study
    • DOI 10.1111/j.1464-5491.2004.01194.x
    • Rachmani R, Slavachevsky I, Amit M, et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study. Diabet Med. 2004;21:471-5. (Pubitemid 38608536)
    • (2004) Diabetic Medicine , vol.21 , Issue.5 , pp. 471-475
    • Rachmani, R.1    Slavachevsky, I.2    Amit, M.3    Levi, Z.4    Kedar, Y.5    Berla, M.6    Ravid, M.7
  • 87
    • 0037222490 scopus 로고    scopus 로고
    • Effectiveness of aldosterone blockade in patients with diabetic nephropathy
    • DOI 10.1161/01.HYP.0000044937.95080.E9
    • Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64-8. (Pubitemid 36056793)
    • (2003) Hypertension , vol.41 , Issue.1 , pp. 64-68
    • Sato, A.1    Hayashi, K.2    Naruse, M.3    Saruta, T.4
  • 88
    • 24144495285 scopus 로고    scopus 로고
    • Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study
    • DOI 10.2337/diacare.28.9.2106
    • Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care. 2005;28:2106-12. (Pubitemid 41242452)
    • (2005) Diabetes Care , vol.28 , Issue.9 , pp. 2106-2112
    • Rossing, K.1    Schjoedt, K.J.2    Smidt, U.M.3    Boomsma, F.4    Parving, H.-H.5
  • 90
    • 33745209933 scopus 로고    scopus 로고
    • Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensinconverting enzyme inhibitor
    • Ogawa S, Takeuchi K, Mori T, et al. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensinconverting enzyme inhibitor. Clin Exp Pharmacol Physiol. 2006;33:477-9.
    • (2006) Clin Exp Pharmacol Physiol , vol.33 , pp. 477-9
    • Ogawa, S.1    Takeuchi, K.2    Mori, T.3
  • 92
    • 20544465842 scopus 로고    scopus 로고
    • Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study
    • DOI 10.1053/j.ajkd.2005.03.007, PII S0272638605004348
    • Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study. Am J Kidney Dis. 2005;46:45-51. (Pubitemid 40848432)
    • (2005) American Journal of Kidney Diseases , vol.46 , Issue.1 , pp. 45-51
    • Bianchi, S.1    Bigazzi, R.2    Campese, V.M.3
  • 93
    • 72049109463 scopus 로고    scopus 로고
    • Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy
    • Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641-50.
    • (2009) J Am Soc Nephrol , vol.20 , pp. 2641-50
    • Mehdi, U.F.1    Adams-Huet, B.2    Raskin, P.3
  • 94
    • 0030459918 scopus 로고    scopus 로고
    • Renal protection in diabetes: An emerging role for calcium antagonists
    • Parving HH, Tarnow L, Rossing P. Renal protection in diabetes: An emerging role for calcium antagonists. J Hypertens Suppl. 1996;14: S21-5.
    • (1996) J Hypertens Suppl , vol.14
    • Parving, H.H.1    Tarnow, L.2    Rossing, P.3
  • 95
    • 0024205652 scopus 로고
    • Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy
    • Mimran A, Insua A, Ribstein J, et al. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Diabetes Care. 1988;11:850-3. (Pubitemid 19006528)
    • (1988) Diabetes Care , vol.11 , Issue.10 , pp. 850-853
    • Mimran, A.1    Insua, A.2    Ribstein, J.3    Bringer, J.4    Monnier, L.5
  • 96
    • 0024539169 scopus 로고
    • Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: A randomised controlled trial
    • Baba T, Murabayashi S, Takebe K. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: A randomised controlled trial. Diabetologia. 1989;32:40-4. (Pubitemid 19061740)
    • (1989) Diabetologia , vol.32 , Issue.1 , pp. 40-44
    • Baba, T.1    Murabayashi, S.2    Takebe, K.3
  • 97
    • 0025963419 scopus 로고
    • Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria
    • Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group. BMJ. 1991;302:210-216.
    • (1991) Melbourne Diabetic Nephropathy Study Group. BMJ , vol.302 , pp. 210-216
  • 98
    • 0001859442 scopus 로고    scopus 로고
    • Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes
    • Mosconi L, Ruggenenti P, Perna A, et al. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int Suppl. 1996;55:S91-3.
    • (1996) Kidney Int Suppl , vol.55
    • Mosconi, L.1    Ruggenenti, P.2    Perna, A.3
  • 99
    • 0028812748 scopus 로고
    • Hypertension and non-insulindependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist
    • Crepaldi G, Carraro A, Brocco E, et al. Hypertension and non-insulindependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist. Acta Diabetol. 1995;32:203-8.
    • (1995) Acta Diabetol , vol.32 , pp. 203-8
    • Crepaldi, G.1    Carraro, A.2    Brocco, E.3
  • 101
    • 0001044921 scopus 로고    scopus 로고
    • Effect of amlopidine vs. fosinopril on microalbuminuria in elderly hypertensive patients with type II diabetes
    • Corradi LLP, Pasotti C, Zoppi A, Preti P, Lazzari P, et al. Effect of amlopidine vs. fosinopril on microalbuminuria in elderly hypertensive patients with type II diabetes. Am J Hypertens. 1996;9:152A.
    • (1996) Am J Hypertens , vol.9
    • Corradi, L.L.P.1    Pasotti, C.2    Zoppi, A.3    Preti, P.4    Lazzari, P.5
  • 102
    • 0343957436 scopus 로고
    • Comparative study on renal effects of nitrendipine vs. enalapril in microalbuminuric patients with type 1 diabetes mellitus
    • Jungmann EHT, Malanyn M, Mortasawi N, Schererich J, Usadel KH. Comparative study on renal effects of nitrendipine vs. enalapril in microalbuminuric patients with type 1 diabetes mellitus. Diabetologia. 1992;35:A149.
    • (1992) Diabetologia , vol.35
    • Jungmann, E.H.T.1    Malanyn, M.2    Mortasawi, N.3    Schererich, J.4    Usadel, K.H.5
  • 103
    • 0024331937 scopus 로고
    • Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy
    • Stornello M, Valvo EV, Scapellato L. Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol. 1989;14:851-5. (Pubitemid 20008843)
    • (1989) Journal of Cardiovascular Pharmacology , vol.14 , Issue.6 , pp. 851-855
    • Stornello, M.1    Valvo, E.V.2    Scapellato, L.3
  • 104
    • 0025217243 scopus 로고
    • Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus
    • Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990;112:707-8. (Pubitemid 20137180)
    • (1990) Annals of Internal Medicine , vol.112 , Issue.9 , pp. 707-708
    • Bakris, G.L.1
  • 105
    • 0026806608 scopus 로고
    • Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients
    • Romero R, Salinas I, Lucas A, et al. Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients. Diabetes Res Clin Pract. 1992;17:191-8.
    • (1992) Diabetes Res Clin Pract , vol.17 , pp. 191-8
    • Romero, R.1    Salinas, I.2    Lucas, A.3
  • 106
    • 0026600686 scopus 로고
    • Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients
    • Ferder L, Daccordi H, Martello M, et al. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension. 1992;19:II237-42.
    • (1992) Hypertension , vol.19 , pp. 237-242
    • Ferder, L.1    Daccordi, H.2    Martello, M.3
  • 107
    • 0026534833 scopus 로고
    • Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection
    • Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int. 1992;41:912-9.
    • (1992) Kidney Int , vol.41 , pp. 912-9
    • Bakris, G.L.1    Barnhill, B.W.2    Sadler, R.3
  • 108
    • 0027772076 scopus 로고
    • A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension
    • Norgaard K, Jensen T, Christensen P, et al. A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension. Blood Press. 1993;2:301-8. (Pubitemid 24026309)
    • (1993) Blood Pressure , vol.2 , Issue.4 , pp. 301-308
    • Norgaard, K.1    Jensen, T.2    Christensen, P.3    Feldt-Rasmussen, B.4
  • 109
    • 0031051404 scopus 로고    scopus 로고
    • Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment
    • Rossing P, Tarnow L, Boelskifte S, et al. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes. 1997;46:481-7. (Pubitemid 27090279)
    • (1997) Diabetes , vol.46 , Issue.3 , pp. 481-487
    • Rossing, P.1    Tarnow, L.2    Boelskifte, S.3    Jensen, B.R.4    Nielsen, F.S.5    Parving, H.-H.6
  • 110
    • 24844476907 scopus 로고    scopus 로고
    • Long term effects of ramipril and nitrendipine on albuminuria in diabetic hypertensive patients with impaired renal function
    • Corradi LFR, Zoppi A, Lusardi P, Preti P, Lazzari P, et al. Long term effects of ramipril and nitrendipine on albuminuria in diabetic hypertensive patients with impaired renal function. Am J Hypertens. 1996;9:151A.
    • (1996) Am J Hypertens , vol.9
    • Corradi, L.F.R.1    Zoppi, A.2    Lusardi, P.3    Preti, P.4    Lazzari, P.5
  • 111
    • 0000645687 scopus 로고
    • Effect of nondihydropyridine calcium antagonists (NDCAs) on progression of nephropathy from noninsulin dependent diabetes (NIDDM
    • Bakris GL CJ, Vicknair N, Leurgans S. Effect of nondihydropyridine calcium antagonists (NDCAs) on progression of nephropathy from noninsulin dependent diabetes (NIDDM). J Am Soc Nephrol. 1995;6:446.
    • (1995) J Am Soc Nephrol , vol.6 , pp. 446
    • Bakris, G.L.C.J.1    Vicknair, N.2    Leurgans, S.3
  • 112
    • 24844463607 scopus 로고
    • Comparative study of lisinopril and nifedipine in treatment of diabetic patients with hypertension and macroproteinuria
    • O'Donnell MJ, Rowe B, Lawson N, Horton A, Gide OHV, Barnett AH. Comparative study of lisinopril and nifedipine in treatment of diabetic patients with hypertension and macroproteinuria. Diabetes. 1991;40:505A.
    • (1991) Diabetes , vol.40
    • O'Donnell, M.J.1    Rowe, B.2    Lawson, N.3    Horton, A.4    Gide, O.H.V.5    Barnett, A.H.6
  • 113
    • 1842330085 scopus 로고
    • Lisinopril but not nifedipine reduces urinary albumin excretion in diabetic nephropathy
    • Holdaas H, Hartmann A, Lien MG, Nielsen L, Fauchald T, Jervell J, et al. Lisinopril but not nifedipine reduces urinary albumin excretion in diabetic nephropathy. Kidney Int. 1990;37:239.
    • (1990) Kidney Int , vol.37 , pp. 239
    • Holdaas, H.1    Hartmann, A.2    Lien, M.G.3    Nielsen, L.4    Fauchald, T.5    Jervell, J.6
  • 114
    • 57349138291 scopus 로고    scopus 로고
    • Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
    • Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-28.
    • (2008) N Engl J Med , vol.359 , pp. 2417-28
    • Jamerson, K.1    Weber, M.A.2    Bakris, G.L.3
  • 115
    • 77950187294 scopus 로고    scopus 로고
    • Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial
    • Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173-81.
    • (2010) Lancet , vol.375 , pp. 1173-81
    • Bakris, G.L.1    Sarafidis, P.A.2    Weir, M.R.3
  • 116
    • 2442703942 scopus 로고    scopus 로고
    • Differential effects of calcium antagonist subclasses on markers of nephropathy progression
    • DOI 10.1111/j.1523-1755.2004.00620.x
    • Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991-2002. (Pubitemid 38669986)
    • (2004) Kidney International , vol.65 , Issue.6 , pp. 1991-2002
    • Bakris, G.L.1    Weir, M.R.2    Secic, M.3    Campbell, B.4    Weis-McNulty, A.5
  • 117
    • 0031042356 scopus 로고    scopus 로고
    • Understanding the nature of renal disease progression
    • Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997;51:2-15. (Pubitemid 27064516)
    • (1997) Kidney International , vol.51 , Issue.1 , pp. 2-15
    • Remuzzi, G.1    Ruggenenti, P.2    Benigni, A.3
  • 119
    • 0028887054 scopus 로고
    • Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials
    • Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10:1963-74.
    • (1995) Nephrol Dial Transplant , vol.10 , pp. 1963-74
    • Gansevoort, R.T.1    Sluiter, W.J.2    Hemmelder, M.H.3
  • 120
    • 0029961207 scopus 로고    scopus 로고
    • Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
    • Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641-50. (Pubitemid 26364270)
    • (1996) Kidney International , vol.50 , Issue.5 , pp. 1641-1650
    • Bakris, G.L.1    Copley, J.B.2    Vicknair, N.3    Sadler, R.4    Leurgans, S.5
  • 121
    • 0031020448 scopus 로고    scopus 로고
    • Effect of calcium channel or β-blockade on the progression of diabetic nephropathy in African Americans
    • Bakris GL, Mangrum A, Copley JB, et al. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997;29:744-50. (Pubitemid 27097979)
    • (1997) Hypertension , vol.29 , Issue.3 , pp. 744-750
    • Bakris, G.L.1    Mangrum, A.2    Copley, J.B.3    Vicknair, N.4    Sadler, R.5
  • 122
    • 0037431774 scopus 로고    scopus 로고
    • Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial
    • DOI 10.1016/S0140-6736(03)12229-5
    • Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet. 2003;361:117-24. (Pubitemid 36092015)
    • (2003) Lancet , vol.361 , Issue.9352 , pp. 117-124
    • Nakao, N.1    Yoshimura, A.2    Morita, H.3    Takada, M.4    Kayano, T.5    Ideura, T.6
  • 123
    • 0032911972 scopus 로고    scopus 로고
    • Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation
    • Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis. 1999;33:1004-10. (Pubitemid 29214705)
    • (1999) American Journal of Kidney Diseases , vol.33 , Issue.5 , pp. 1004-1010
    • Keane, W.F.1    Eknoyan, G.2    Willis, K.3
  • 124
    • 0030980370 scopus 로고    scopus 로고
    • Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy
    • Nielsen FS, Rossing P, Gall MA, et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes. 1997;46:1182-8. (Pubitemid 27271080)
    • (1997) Diabetes , vol.46 , Issue.7 , pp. 1182-1188
    • Nielsen, F.S.1    Rossing, P.2    Gall, M.-A.3    Skott, P.4    Smidt, U.M.5    Parving, H.-H.6
  • 125
    • 0032511601 scopus 로고    scopus 로고
    • Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
    • UK Prospective Diabetes Study Group
    • Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317:713-720.
    • (1998) BMJ , vol.317 , pp. 713-720
  • 127
    • 43749112197 scopus 로고    scopus 로고
    • Effects of different ACE inhibitor combinations on albuminuria: Results of the GUARD study
    • DOI 10.1038/ki.2008.102, PII KI2008102
    • Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: Results of the GUARD study. Kidney Int. 2008;73:1303-9. (Pubitemid 351693145)
    • (2008) Kidney International , vol.73 , Issue.11 , pp. 1303-1309
    • Bakris, G.L.1    Toto, R.D.2    McCullough, P.A.3    Rocha, R.4    Purkayastha, D.5    Davis, P.6
  • 128
    • 83055172414 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease
    • National Kidney Foundation
    • National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41:S1-92.
    • (2003) Am J Kidney Dis , vol.41
  • 130
    • 32544443164 scopus 로고    scopus 로고
    • Review: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia
    • DOI 10.1210/jc.2005-2084
    • Ginsberg HN. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 2006;91:383-92. (Pubitemid 43236897)
    • (2006) Journal of Clinical Endocrinology and Metabolism , vol.91 , Issue.2 , pp. 383-392
    • Ginsberg, H.N.1
  • 131
    • 0026710526 scopus 로고
    • Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study
    • Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820-5.
    • (1992) Diabetes Care , vol.15 , pp. 820-5
    • Koskinen, P.1    Manttari, M.2    Manninen, V.3
  • 133
    • 0037132607 scopus 로고    scopus 로고
    • Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHATLLT
    • Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHATLLT). JAMA. 2002;288:2998-3007.
    • (2002) JAMA , vol.288 , pp. 2998-3007
  • 134
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial
    • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7-22.
    • (2002) Lancet , vol.360 , pp. 7-22
  • 135
    • 0037840242 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-control led trial
    • Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-control led trial . Lancet. 2003;361:2005-16.
    • (2003) Lancet , vol.361 , pp. 2005-16
    • Collins, R.1    Armitage, J.2    Parish, S.3
  • 138
    • 4444382862 scopus 로고    scopus 로고
    • Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus background paper for the American College of Physicians
    • Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: Background paper for the American College of Physicians. Ann Intern Med. 2004;140:650-8.
    • (2004) Ann Intern Med , vol.140 , pp. 650-8
    • Vijan, S.1    Hayward, R.A.2
  • 139
    • 0037458229 scopus 로고    scopus 로고
    • Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency
    • Tonelli M, Moye L, Sacks FM, et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138:98-104. (Pubitemid 36222496)
    • (2003) Annals of Internal Medicine , vol.138 , Issue.2 , pp. 98-104
    • Tonelli, M.1    Moye, L.2    Sacks, F.M.3    Kiberd, B.4    Curhan, G.5
  • 141
    • 33748161712 scopus 로고    scopus 로고
    • Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease
    • DOI 10.1093/ndt/gfl198
    • Jones C, Roderick P, Harris S, et al. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant. 2006;21:2133-43. (Pubitemid 44313384)
    • (2006) Nephrology Dialysis Transplantation , vol.21 , Issue.8 , pp. 2133-2143
    • Jones, C.1    Roderick, P.2    Harris, S.3    Rogerson, M.4
  • 142
    • 36448979949 scopus 로고    scopus 로고
    • Outcomes in patients with chronic kidney disease referred late to nephrologists: A meta-analysis
    • Chan MR, Dall AT, Fletcher KE, et al. Outcomes in patients with chronic kidney disease referred late to nephrologists: A meta-analysis. Am J Med. 2007;120:1063-70.
    • (2007) Am J Med , vol.120 , pp. 1063-70
    • Chan, M.R.1    Dall, A.T.2    Fletcher, K.E.3
  • 143
    • 0037163490 scopus 로고    scopus 로고
    • Nephrologist care and mortality in patients with chronic renal insufficiency
    • Avorn J, Bohn RL, Levy E, et al. Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med. 2002;162:2002-6.
    • (2002) Arch Intern Med , vol.162 , pp. 2002-6
    • Avorn, J.1    Bohn, R.L.2    Levy, E.3
  • 145
    • 0036849925 scopus 로고    scopus 로고
    • The role of comprehensive renal clinic in chronic kidney disease stabilization and management: The Northwestern experience
    • Ghossein C, Serrano A, Rammohan M, et al. The role of comprehensive renal clinic in chronic kidney disease stabilization and management: The Northwestern experience. Semin Nephrol. 2002;22:526-32. (Pubitemid 35351264)
    • (2002) Seminars in Nephrology , vol.22 , Issue.6 , pp. 526-532
    • Ghossein, C.1    Serrano, A.2    Rammohan, M.3    Batlle, D.4
  • 146
    • 0035786908 scopus 로고    scopus 로고
    • Insulin resistance and its treatment by thiazolidinediones
    • Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res. 2001;56:265-94.
    • (2001) Recent Prog Horm Res , vol.56 , pp. 265-94
    • Lebovitz, H.E.1    Banerji, M.A.2
  • 148
    • 0842289940 scopus 로고    scopus 로고
    • In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control
    • DOI 10.2337/diacare.27.2.484
    • Pistrosch F, Passauer J, Fischer S, et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care. 2004;27:484-90. (Pubitemid 38174076)
    • (2004) Diabetes Care , vol.27 , Issue.2 , pp. 484-490
    • Pistrosch, F.1    Passauer, J.2    Fischer, S.3    Fuecker, K.4    Hanefeld, M.5    Gross, P.6
  • 149
    • 0031888958 scopus 로고    scopus 로고
    • PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
    • DOI 10.1038/34184
    • Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-6. (Pubitemid 28079219)
    • (1998) Nature , vol.391 , Issue.6662 , pp. 82-86
    • Jiang, C.1    Ting, A.T.2    Seed, B.3
  • 150
    • 17644423543 scopus 로고    scopus 로고
    • Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone
    • DOI 10.1161/01.CIR.0000161954.17870.5D
    • Harte A, McTernan P, Chetty R, et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation. 2005;111:1954-61. (Pubitemid 40570215)
    • (2005) Circulation , vol.111 , Issue.15 , pp. 1954-1961
    • Harte, A.1    McTernan, P.2    Chetty, R.3    Coppack, S.4    Katz, J.5    Smith, S.6    Kumar, S.7
  • 151
    • 0034633847 scopus 로고    scopus 로고
    • Peroxisome proliferatoractivated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells
    • Takeda K, Ichiki T, Tokunou T, et al. Peroxisome proliferatoractivated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000;102:1834-9.
    • (2000) Circulation , vol.102 , pp. 1834-9
    • Takeda, K.1    Ichiki, T.2    Tokunou, T.3
  • 152
    • 0034968295 scopus 로고    scopus 로고
    • Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes
    • DOI 10.1291/hypres.24.229
    • Sugawara A, Takeuchi K, Uruno A, et al. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes. Hypertens Res. 2001;24:229-33. (Pubitemid 32577144)
    • (2001) Hypertension Research , vol.24 , Issue.3 , pp. 229-233
    • Sugawara, A.1    Takeuchi, K.2    Uruno, A.3    Ikeda, Y.4    Arima, S.5    Sato, K.6    Kudo, M.7    Taniyama, Y.8    Ito, S.9
  • 153
    • 0033669212 scopus 로고    scopus 로고
    • Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients
    • Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications. 2000;14:250-4.
    • (2000) J Diabetes Complications , vol.14 , pp. 250-4
    • Nakamura, T.1    Ushiyama, C.2    Shimada, N.3
  • 154
    • 0037369871 scopus 로고    scopus 로고
    • PPAR agonists protect mesangial cells from interleukin 1β-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway
    • DOI 10.1097/01.ASN.0000050414.52908.DA
    • Ruan XZ, Moorhead JF, Fernando R, et al. PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol. 2003;14:593-600. (Pubitemid 36246002)
    • (2003) Journal of the American Society of Nephrology , vol.14 , Issue.3 , pp. 593-600
    • Ruan, X.Z.1    Moorhead, J.F.2    Fernando, R.3    Wheeler, D.C.4    Powis, S.H.5    Varghese, Z.6
  • 156
    • 2442678866 scopus 로고    scopus 로고
    • Differential effects of peroxisome proliferator activated receptor-γ (PPARγ) ligands in proximal tubular cells: Thiazolidinediones are partial PPARγ agonists
    • DOI 10.1111/j.1523-1755.2004.00624.x
    • Chana RS, Lewington AJ, Brunskill NJ. Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: Thiazolidinediones are partial PPAR gamma agonists. Kidney Int. 2004;65:2081-90. (Pubitemid 38669994)
    • (2004) Kidney International , vol.65 , Issue.6 , pp. 2081-2090
    • Chana, R.S.1    Lewington, A.J.2    Brunskill, N.J.3
  • 157
    • 4143099046 scopus 로고    scopus 로고
    • The effect of high glucose and PPAR-γ agonists on PPAR-γ expression and function in HK-2 cells
    • DOI 10.1152/ajprenal.00445.2003
    • Panchapakesan U, Pollock CA, Chen XM. The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells. Am J Physiol Renal Physiol. 2004;287:F528-34. (Pubitemid 39095968)
    • (2004) American Journal of Physiology - Renal Physiology , vol.287 , Issue.3
    • Panchapakesan, U.1    Pollock, C.A.2    Chen, X.M.3
  • 158
    • 0030825304 scopus 로고    scopus 로고
    • Antihypertensive and vasculo-and renoprotective effects of pioglitazone in genetically obese diabetic rats
    • Yoshimoto T, Naruse M, Nishikawa M, et al. Antihypertensive and vasculo-and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol. 1997;272:E989-96.
    • (1997) Am J Physiol , vol.272
    • Yoshimoto, T.1    Naruse, M.2    Nishikawa, M.3
  • 159
    • 0031847401 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in zucker fatty rats
    • DOI 10.2337/diabetes.47.8.1326
    • Buckingham RE, Al-Barazanji KA, Toseland CD, et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes. 1998;47:1326-34. (Pubitemid 28357012)
    • (1998) Diabetes , vol.47 , Issue.8 , pp. 1326-1334
    • Buckingham, R.E.1    Al-Barazanji, K.A.2    Toseland, C.D.N.3    Slaughter, M.4    Connor, S.C.5    West, A.6    Bond, B.7    Turner, N.C.8    Clapham, J.C.9
  • 160
    • 0036116895 scopus 로고    scopus 로고
    • Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat
    • DOI 10.1053/meta.2002.30953
    • Yamashita H, Nagai Y, Takamura T, et al. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism. 2002;51:403-8. (Pubitemid 34406552)
    • (2002) Metabolism: Clinical and Experimental , vol.51 , Issue.4 , pp. 403-408
    • Yamashita, H.1    Nagai, Y.2    Takamura, T.3    Nohara, E.4    Kobayashi, K.-I.5
  • 161
    • 0034033786 scopus 로고    scopus 로고
    • Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats
    • Isshiki K, Haneda M, Koya D, et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes. 2000;49:1022-32. (Pubitemid 30349426)
    • (2000) Diabetes , vol.49 , Issue.6 , pp. 1022-1032
    • Isshiki, K.1    Haneda, M.2    Koya, D.3    Maeda, S.4    Sugimoto, T.5    Kikkawa, R.6
  • 162
    • 0345599866 scopus 로고    scopus 로고
    • Peroxisome Proliferator-Activated Receptor γ Agonist Provides Superior Renal Protection versus Angiotensin-Converting Enzyme Inhibition in a Rat Model of Type 2 Diabetes with Obesity
    • DOI 10.1124/jpet.103.055616
    • Baylis C, Atzpodien EA, Freshour G, et al. Peroxisome proliferatoractivated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther. 2003;307:854-60. (Pubitemid 37494201)
    • (2003) Journal of Pharmacology and Experimental Therapeutics , vol.307 , Issue.3 , pp. 854-860
    • Baylis, C.1    Atzpodien, E.-A.2    Freshour, G.3    Engels, K.4
  • 163
    • 0035126947 scopus 로고    scopus 로고
    • Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure
    • DOI 10.1097/00004872-200103000-00019
    • Yoshida K, Kohzuki M, Xu HL, et al. Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure. J Hypertens. 2001;19:503-10. (Pubitemid 32195387)
    • (2001) Journal of Hypertension , vol.19 , Issue.3 , pp. 503-510
    • Yoshida, K.1    Kohzuki, M.2    Xu, H.-L.3    Wu, X.-M.4    Kamimoto, M.5    Sato, T.6
  • 165
    • 0034949794 scopus 로고    scopus 로고
    • Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria
    • DOI 10.1046/j.1464-5491.2001.00463.x
    • Nakamura T, Ushiyama C, Suzuki S, et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med. 2001;18:308-13. (Pubitemid 32579361)
    • (2001) Diabetic Medicine , vol.18 , Issue.4 , pp. 308-313
    • Nakamura, T.1    Ushiyama, C.2    Suzuki, S.3    Shimada, N.4    Sekizuka, K.5    Ebihara, L.6    Koide, H.7
  • 167
    • 1242283924 scopus 로고    scopus 로고
    • Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: A prospective, randomized trial
    • DOI 10.1016/j.amjmed.2003.07.023
    • Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: A prospective, randomized trial. Am J Med. 2004;116:230-5. (Pubitemid 38224230)
    • (2004) American Journal of Medicine , vol.116 , Issue.4 , pp. 230-235
    • Aljabri, K.1    Kozak, S.E.2    Thompson, D.M.3
  • 169
    • 1042268736 scopus 로고    scopus 로고
    • One-year glycemic control with a suifonyurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes
    • DOI 10.2337/diacare.27.1.141
    • Hanefeld M, Brunetti P, Schernthaner GH, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27:141-7. (Pubitemid 38196723)
    • (2004) Diabetes Care , vol.27 , Issue.1 , pp. 141-147
    • Hanefeld, M.1    Brunetti, P.2    Schernthaner, G.H.3    Matthews, D.R.4    Charbonnel, B.H.5
  • 174
    • 21344466513 scopus 로고    scopus 로고
    • Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients
    • DOI 10.2337/diabetes.54.7.2206
    • Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes. 2005;54:2206-11. (Pubitemid 40911285)
    • (2005) Diabetes , vol.54 , Issue.7 , pp. 2206-2211
    • Pistrosch, F.1    Herbrig, K.2    Kindel, B.3    Passauer, J.4    Fischer, S.5    Gross, P.6
  • 175
    • 33748556888 scopus 로고    scopus 로고
    • Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria
    • DOI 10.1097/01.hjh.0000244955.39491.88, PII 0000487220061000000022
    • Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006;24:2047-55. (Pubitemid 44371272)
    • (2006) Journal of Hypertension , vol.24 , Issue.10 , pp. 2047-2055
    • Bakris, G.L.1    Ruilope, L.M.2    McMorn, S.O.3    Weston, W.M.4    Heise, M.A.5    Freed, M.I.6    Porter, L.E.7
  • 176
    • 77954988618 scopus 로고    scopus 로고
    • Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone
    • Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411-8.
    • (2010) JAMA , vol.304 , pp. 411-8
    • Graham, D.J.1    Ouellet-Hellstrom, R.2    MaCurdy, T.E.3
  • 177
    • 33846989363 scopus 로고    scopus 로고
    • The emerging role of angiotensin-converting enzyme-2 in the kidney
    • Burns KD. The emerging role of angiotensin-converting enzyme-2 in the kidney. Curr Opin Nephrol Hypertens. 2007;16:116-21.
    • (2007) Curr Opin Nephrol Hypertens , vol.16 , pp. 116-21
    • Burns, K.D.1
  • 178
    • 6344246036 scopus 로고    scopus 로고
    • Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism
    • DOI 10.1042/BJ20040634
    • Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensinconverting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383:45-51. (Pubitemid 39389449)
    • (2004) Biochemical Journal , vol.383 , Issue.1 , pp. 45-51
    • Rice, G.I.1    Thomas, D.A.2    Grant, P.J.3    Turner, A.J.4    Hooper, N.M.5
  • 179
    • 0036194890 scopus 로고    scopus 로고
    • Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles
    • DOI 10.1161/hy0302.104673
    • Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension. 2002;39:799-802. (Pubitemid 34252879)
    • (2002) Hypertension , vol.39 , Issue.3 , pp. 799-802
    • Ren, Y.1    Garvin, J.L.2    Carretero, O.A.3
  • 180
    • 33750722109 scopus 로고    scopus 로고
    • Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: Implications for albuminuria in diabetes
    • DOI 10.1681/ASN.2006050423
    • Ye M, Wysocki J, William J, et al. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: Implications for albuminuria in diabetes. J Am Soc Nephrol. 2006;17:3067-75. (Pubitemid 44707767)
    • (2006) Journal of the American Society of Nephrology , vol.17 , Issue.11 , pp. 3067-3075
    • Ye, M.1    Wysocki, J.2    William, J.3    Soler, M.J.4    Cokic, I.5    Batlle, D.6
  • 182
    • 0041703027 scopus 로고    scopus 로고
    • Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation
    • Minchenko AG, Stevens MJ, White L, et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J. 2003;17:1514-6.
    • (2003) FASEB J , vol.17 , pp. 1514-6
    • Minchenko, A.G.1    Stevens, M.J.2    White, L.3
  • 183
    • 0031630241 scopus 로고    scopus 로고
    • Renal endothelin system in diabetes: Comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism
    • Hocher B, Lun A, Priem F, et al. Renal endothelin system in diabetes: Comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism. J Cardiovasc Pharmacol. 1998;31(Suppl 1):S492-5. (Pubitemid 128709991)
    • (1998) Journal of Cardiovascular Pharmacology , vol.31 , Issue.SUPPL. 1
    • Hocher, B.1    Lun, A.2    Priem, F.3    Neumayer, H.-H.4    Raschack, M.5
  • 185
    • 0029010570 scopus 로고
    • Defining the role of endothelins in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studies
    • Benigni A. Defining the role of endothelins in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studies. Curr Opin Nephrol Hypertens. 1995;4:349-53.
    • (1995) Curr Opin Nephrol Hypertens , vol.4 , pp. 349-53
    • Benigni, A.1
  • 186
    • 0027739276 scopus 로고
    • Autocrine role of endothelin in rat inner medullary collecting duct: Inhibition of AVP-induced cAMP accumulation
    • Kohan DE. Autocrine role of endothelin in rat inner medullary collecting duct: Inhibition of AVP-induced cAMP accumulation. J Cardiovasc Pharmacol. 1993;22(Suppl 8):S174-9.
    • (1993) J Cardiovasc Pharmacol , vol.22 , Issue.SUPPL. 8
    • Kohan, D.E.1
  • 188
    • 0028344196 scopus 로고
    • Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria
    • Lee YJ, Shin SJ, Tsai JH. Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria. Diabetes Care. 1994;17:263-6.
    • (1994) Diabetes Care , vol.17 , pp. 263-6
    • Lee, Y.J.1    Shin, S.J.2    Tsai, J.H.3
  • 190
    • 0035015691 scopus 로고    scopus 로고
    • The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus
    • DOI 10.1016/S1056-8727(01)00137-4, PII S1056872701001374
    • Ak G, Buyukberber S, Sevinc A, et al. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus. J Diabetes Complications. 2001;15:150-7. (Pubitemid 32453172)
    • (2001) Journal of Diabetes and its Complications , vol.15 , Issue.3 , pp. 150-157
    • Ak, G.1    Buyukberber, S.2    Sevinc, A.3    Turk, H.M.4    Ates, M.5    Sari, R.6    Savli, H.7    Cigli, A.8
  • 191
    • 0036657216 scopus 로고    scopus 로고
    • Haemodynamics in microvascular complications in type 1 diabetes
    • Candido R, Allen TJ. Haemodynamics in microvascular complications in type 1 diabetes. Diabetes Metab Res Rev. 2002;18:286-304.
    • (2002) Diabetes Metab Res Rev , vol.18 , pp. 286-304
    • Candido, R.1    Allen, T.J.2
  • 192
    • 41749086422 scopus 로고    scopus 로고
    • Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus
    • Zanatta CM, Gerchman F, Burttet L, et al. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;80:299-304.
    • (2008) Diabetes Res Clin Pract , vol.80 , pp. 299-304
    • Zanatta, C.M.1    Gerchman, F.2    Burttet, L.3
  • 193
    • 33845261609 scopus 로고    scopus 로고
    • Endothelin-A receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia
    • DOI 10.1681/ASN.2006060635
    • Chade AR, Krier JD, Textor SC, et al. Endothelin-a receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia. J Am Soc Nephrol. 2006;17: 3394-403. (Pubitemid 44865282)
    • (2006) Journal of the American Society of Nephrology , vol.17 , Issue.12 , pp. 3394-3403
    • Chade, A.R.1    Krier, J.D.2    Textor, S.C.3    Lerman, A.4    Lerman, L.O.5
  • 195
    • 11144267307 scopus 로고    scopus 로고
    • Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats
    • DOI 10.1097/01.fjc.0000166208.12297.8d
    • Thone-Reinke C, Simon K, Richter CM, et al. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J Cardiovasc Pharmacol. 2004;44(Suppl 1):S76-9. (Pubitemid 40039648)
    • (2004) Journal of Cardiovascular Pharmacology , vol.44 , Issue.SUPPL. 1
    • Thone-Reinke, C.1    Simon, K.2    Richter, C.-M.3    Godes, M.4    Neumayer, H.-H.5    Thormahlen, D.6    Hocher, B.7
  • 197
    • 0141590203 scopus 로고    scopus 로고
    • Renal damage in the SHR/N-cp type 2 diabetes model: Comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker
    • DOI 10.1097/01.LAB.0000085188.23709.29
    • Gross ML, Ritz E, Schoof A, et al. Renal damage in the SHR/N-cp type 2 diabetes model: Comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab Investig. 2003;83:1267-77. (Pubitemid 37140311)
    • (2003) Laboratory Investigation , vol.83 , Issue.9 , pp. 1267-1277
    • Gross, M.-L.1    Ritz, E.2    Schoof, A.3    Helmke, B.4    Parkman, A.5    Tulp, O.6    Munter, K.7    Amann, K.8
  • 199
  • 200
    • 33750243479 scopus 로고    scopus 로고
    • The ETA-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy
    • Wenzel RR et al. The ETA-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy. ASN Renal Week 2005.
    • (2005) ASN Renal Week
    • Wenzel, R.R.1
  • 201
    • 77949877308 scopus 로고    scopus 로고
    • Avosentan for overt diabetic nephropathy
    • Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21:527-35.
    • (2010) J Am Soc Nephrol , vol.21 , pp. 527-35
    • Mann, J.F.1    Green, D.2    Jamerson, K.3
  • 202
    • 0035834748 scopus 로고    scopus 로고
    • Amides are novel protein modifications formed by physiological sugars
    • Glomb MA, Pfahler C. Amides are novel protein modifications formed by physiological sugars. J Biol Chem. 2001;276:41638-47.
    • (2001) J Biol Chem , vol.276 , pp. 41638-47
    • Glomb, M.A.1    Pfahler, C.2
  • 203
    • 0023950461 scopus 로고
    • Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
    • Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315-21.
    • (1988) N Engl J Med , vol.318 , pp. 1315-21
    • Brownlee, M.1    Cerami, A.2    Vlassara, H.3
  • 206
    • 12144257117 scopus 로고    scopus 로고
    • Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease
    • Williams ME. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Curr Diab Rep. 2004;4:441-6. (Pubitemid 40104220)
    • (2004) Current Diabetes Reports , vol.4 , Issue.6 , pp. 441-446
    • Williams, M.E.1
  • 207
    • 12144263911 scopus 로고    scopus 로고
    • A phase 2 clinical trial of pyridoxamine (Pyridorin) in type 1 and type 2 diabetic patients with overt nephropathy (PYR-206
    • Williams ME. A phase 2 clinical trial of pyridoxamine (Pyridorin) in type 1 and type 2 diabetic patients with overt nephropathy (PYR-206). J Am Soc Nephrol. 2003;2003:7A.
    • (2003) J Am Soc Nephrol , vol.2003
    • Williams, M.E.1
  • 209
    • 0142121508 scopus 로고    scopus 로고
    • Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
    • DOI 10.1016/j.abb.2003.08.016
    • Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys. 2003;419:89-96. (Pubitemid 37272162)
    • (2003) Archives of Biochemistry and Biophysics , vol.419 , Issue.1 , pp. 89-96
    • Vasan, S.1    Foiles, P.2    Founds, H.3
  • 210
    • 78149359262 scopus 로고    scopus 로고
    • Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial
    • de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet. 2010;376:1543-51.
    • (2010) Lancet , vol.376 , pp. 1543-51
    • De Zeeuw, D.1    Agarwal, R.2    Amdahl, M.3
  • 211
    • 79954582442 scopus 로고    scopus 로고
    • Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD
    • Pergola PE, Krauth M, Huff JW, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol. 2011;33:469-76.
    • (2011) Am J Nephrol , vol.33 , pp. 469-76
    • Pergola, P.E.1    Krauth, M.2    Huff, J.W.3
  • 212
    • 79960855656 scopus 로고    scopus 로고
    • Bardoxolone methyl and kidney function in CKD with type 2 diabetes
    • Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011.
    • (2011) N Engl J Med
    • Pergola, P.E.1    Raskin, P.2    Toto, R.D.3
  • 213
    • 33845996154 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2007
    • Standards of medical care in diabetes-2007. Diabetes Care. 2007;30 (Suppl 1):S4-S41.
    • (2007) Diabetes Care , vol.30 , Issue.SUPPL. 1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.